CB 2679d Brings Clotting Protein Levels Closer to Normal in Hemophilia B Patients, Phase 1/2 Data Show
Treatment with CB 2679d increased factor IX activity levels in the blood, bringing them closer to normal levels in the newest…
Articles by Patricia Inácio, PhD
Data Supports Potential for Personalized Hemophilia A Therapy with Nuwiq, WFH Presentations Show
Since every hemophilia A patient responds differently to therapies, researchers are working to develop personalized preventive (prophylaxis) strategies with…
Hemophilia Patients Want to Lead More Active Lives, Survey Results Indicate
Preliminary results from the U.S. part of Bayer’s global HemACTIVE patient survey show that a majority of hemophilia patients…
Hemlibra Looks to Reach ‘Ultimate Goal’ of Treating All with Hemophilia A and with Choice in Dosing, Genentech Director Says
Should regulatory authorities agree with favorable results from Genentech’s ongoing Phase 3 studies of Hemlibra (emicizumab-kxwh), hemophilia A patients may…
Hemlibra Ably Treats Hemophilia A Patients Regardless of Inhibitor Status, Data from 2 Phase 3 Trials Show
Data from ongoing Phase 3 clinical trials show that Genentech’s Hemlibra (emicizumab-kxwh) prophylaxis — or preventive treatment —…
Valoctocogene Roxaparvovec Study Doses 1st Hemophilia Patient with Pre-existing AAV5 Antibodies
A Phase 1/2 trial (NCT03520712) testing BioMarin Pharmaceutical’s investigational gene therapy valoctocogene roxaparvovec in severe hemophilia A patients with…
IV Self-Infusion Training Significantly Reduced Infections After Joint Replacement Surgery
Teaching hemophilia patients who have undergone joint replacement surgery how to administer their intravenous (IV) self-infusions in sterility, can decrease…
Hemlibra is an Effective and Cost-saving Hemophila A Therapy, Report Finds
Hemlibra (emicizumab) is an effective and less costly therapy for hemophilia A patients who have substances in their blood that…
Early Analysis Supports Eloctate Use in ITI Therapy for Severe Hemophilia A
Eloctate use in immune tolerance induction (ITI) therapy shows promise in high-risk patients with severe hemophilia A and inhibitors…
Hemophilia B Bleeding-control Treatment Rebinyn Available in the United States
The hemophilia B treatment Rebinyn is available in the United States, its maker Novo Nordisk reports. Rebinyn, which is administered intravenously,…